Message from Our Founder
June 15, 2020
6th Wave Innovations Corp had a transformational year in 2019 culminating in the completion of our merger with Sixth Wave Innovations Inc. this February. As we proceed through the halfway point of 2020 the Company has not been immune to the challenges presented by the COVID-19 pandemic. While this has delayed our targets for rolling out our Affinity™ platform and becoming revenue generating we have powered through the worst and adjusted our strategy. This has included significant resource allocation to expansion of our own facilities and team. We have signed contracts for delivery of multiple Affinity™ units, generated a strong pipeline of interest, signed or in negotiation of supply agreements, and are on pace to deliver our first revenue generating machines in the coming months.
In keeping with our Corporate goals to evolve as a leading supplier of nanotechnology solutions focused on highly profitable and socially relevant innovations this year has seen the Company submit multiple new patents, seen issuance of our patents on a worldwide basis, and demonstrated our ability to quickly and effectively address potential new markets. Specifically, in response to the pandemic, Sixth Wave has developed new intellectual property for the detection of viruses and garnered support for the development from the Canadian Government, National Laboratories, and critical manufacturing partners. Our ability to respond to a critical world health and economic threat comes from the Company’s historic successes and good standing. We are thrilled and energized about the growth opportunities before us and to be able to participate on the world stage to solve this and other difficult problems.
Sixth Wave is helping to ushering the nanotechnology revolution that will optimize commercially viable molecular extraction and detection processes that can increase yields and improve efficiencies for our customers. We are confident our IXOS® mining products, Affinity™ cannabinoid purification platform, Advanced Molecularly Imprinted Polymers Systems (AMIPS™) for virus detection (under development), and ready for commercialization Pathogenic Amine Detection System (PADS™) promise unprecedented value and increased profits for our clients. If we are successful in achieving those goals, this diversified and growing set of product offerings will result in long term growth and stability of the Company and exceptional value to our shareholders.